Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Clinical chapter 01 · Professionals · English

Diagnosis and classification: keep the tasks separate

Use criteria in their intended population and preserve the uncertainty in each input. A calculated classification result is not an individual diagnostic probability.

Olga Goodman, MD · Evidence checked: 25 September 2026

Build and revise the clinical hypothesis

Start with the presentation, time course and credible evidence of inflammation. Establish whether the main question is axial disease, peripheral arthritis, enthesitis, dactylitis or a combination. Examine psoriasis and nails, review documented uveitis and IBD, and distinguish a preceding infection from a coincidental illness. Consider disease prevalence and competing explanations before interpreting HLA-B27 or imaging. Normal inflammatory markers and HLA-B27 negativity do not independently exclude SpA.

ASAS axial criteria

The intended entry population has chronic back pain for at least three months with onset before age 45. Inflammatory back pain is an SpA feature, not an additional mandatory entry requirement. The imaging arm combines sacroiliitis on imaging with at least one SpA feature; the clinical arm uses HLA-B27 with at least two other features. These rules define classification performance in a selected population. They should not be applied as a screening diagnosis to unselected back pain. Negative, positive and unavailable X-ray information must remain distinct.

Modified New York and CASPAR answer different questions

Modified New York definite AS classification requires the radiographic threshold plus a clinical criterion; pain alone does not establish radiographic disease. CASPAR begins with inflammatory articular disease of joints, spine or entheses and then requires at least three points. Current psoriasis scores two points; personal or family history is not added as another psoriasis category when current psoriasis is counted. Nail dystrophy, rheumatoid-factor negativity, dactylitis and qualifying juxta-articular new bone formation contribute under their definitions. Positive rheumatoid factor does not automatically exclude PsA.

Peripheral criteria and historical frameworks

ASAS peripheral criteria require an appropriate current peripheral entry manifestation. Other peripheral features can be historical, but the same entry feature should not simply be counted twice to manufacture the second route. ESSG, Amor and historical Rome/New York frameworks belong in a discussion of how concepts developed; mixing their entry rules and weights creates an unvalidated hybrid. Childhood-onset disease has distinct ILAR categories and evolving PRINTO proposals; adult checklists do not settle a paediatric diagnosis.

Discordance is useful information

When classification and clinical judgement diverge, revisit the validity of individual findings, study quality, alternative diagnoses and the intended use of the criteria. Record why the diagnosis is supported or uncertain. In an acutely swollen joint, exclude infection or crystal disease as indicated rather than allowing a pre-existing SpA label to close the assessment. Reassessment should have a question and a follow-up plan, not endless indiscriminate testing.

Sources & further reading
  1. NICE NG65: Spondyloarthritis in over 16s — diagnosis and management
  2. ASAS axial SpA classification criteria: validation and final selection (2009)
  3. ASAS peripheral SpA classification criteria (2011)
  4. CASPAR: classification criteria for psoriatic arthritis (2006)
  5. ASAS consensus on the nomenclature of axial spondyloarthritis (2024)

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Spondyloarthritis